Clinical Trials Browser

INDUSTRY × sotorasib × 1 year × Clear all

NCT06333951 2026-04-13

Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT07172919 2026-04-09

A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation

Phase 2 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT04892017 2026-04-08

Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT07143513 2026-04-07

Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients

Carcinoma, Non-Small-Cell Lung

NCT06252649 2026-04-02

CodeBreaK 301

Phase 3 Recruiting

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT04303780 2026-03-27

Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

Phase 3 Active not recruiting

345 enrolled 11 charts

KRAS p, G12c Mutated /Advanced Metastatic NSCLC

NCT04380753 2026-03-25

AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).

Phase 1 Completed

12 enrolled 12 charts

Other solid neoplasm

Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation

NCT06804824 2026-03-18

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT03600883 2026-03-16

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Phase 1/2 Active not recruiting

713 enrolled 2 FDA

Other solid neoplasm

KRAS p.G12C Mutant Advanced Solid Tumors

NCT05920356 2026-02-27

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT05198934 2026-02-06

CodeBreak300

Phase 3 Active not recruiting

160 enrolled 3 FDA

Gastrointestinal

Colorectal Neoplasms

NCT06497556 2026-01-20

Krascendo 1

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05074810 2026-01-12

RAMP203

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05054725 2026-01-06

Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

Phase 2 Completed

47 enrolled 17 charts

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Respiratory Tract Diseases, Respiratory Tract Neoplasms

NCT04185883 2025-10-22

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Phase 1 Active not recruiting

Other solid neoplasmSarcoma

Advanced Solid Tumors

NCT04933695 2025-10-22

CodeBreaK201

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT04667234 2025-08-13

Expanded Access of Sotorasib

No longer available

Carcinoma, Non-Small-Cell Lung

NCT05374538 2025-05-01

VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer

Phase 1 Terminated

3 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung